Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 10/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21950956 | 0.84 | KCNA3 (0.49) | KCNA3MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL2260593 | 0.81 | KCNA3 (0.42) | KCNA3CDC25BMEN1LMNAHPGD | |
| SCHEMBL3253868 | 0.78 | ALDH1A1 (0.49) | KCNA3NLRP3CDC25BMEN1ALDH1A1 | |
| SCHEMBL28125752 | 0.75 | ALDH1A1 (0.56) | KCNA3NLRP3MEN1ALDH1A1LMNA | |
| SCHEMBL14124722 | 0.73 | CDC25B (0.64) | CDC25BMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL5722963 | 0.73 | HPGD (0.47) | KCNA3NLRP3MEN1ALDH1A1LMNA | |
| SCHEMBL2260596 | 0.73 | PDE4A (0.49) | CDC25B | |
| SCHEMBL3836766 | 0.72 | CA9 (0.48) | KCNA3MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL17821978 | 0.72 | NLRP3 (0.50) | KCNA3NLRP3MEN1ALDH1A1LMNA | |
| SCHEMBL17821981 | 0.72 | NLRP3 (0.50) | KCNA3NLRP3MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | KCNA3 2940/4885NLRP3 1451/4885CDC25B 572/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | KCNA3 2940/4885NLRP3 1451/4885CDC25B 572/4885 |
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | KCNA3 2267/4885NLRP3 4806/4885CDC25B 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.